PLAY RECORDING

Overview:

In recent years, the hope on solving the patent eligibility conundrum is still up in the air. Precedential decisions interpreting and applying Section 101 from both the Supreme Court and the Federal Circuit created tangled patent eligibility rulings that have limited the ability to patent certain technologies. In connection with this, earlier this year, the members of the Senate Judiciary Subcommittee on Intellectual Property, along with members of the House, have produced a draft bill that will revise 35 U.S.C. Section 101. However, this draft bill is not yet available for there are still a lot of details to be discussed, and the proposed legislation is still to be determined.  A mutual effort to produce a consistent subject matter eligibility framework is both an achievement and a raising opportunity for the year ahead.

In this LIVE Webcast, a seasoned panel of thought leaders and professionals brought together by The Knowledge Group will provide and present to the audience an in-depth analysis of the fundamentals as well as recent developments in Overcoming Sections 101,102, 103 Conundrum for Biotech and Chemical Patents. Speakers will also present all the important issues surrounding this significant topic including its impact on Biotech and Chemical Patents.

Credit:

Course Level:

Intermediate

 

Advance Preparation:

Print and review course materials

 

Method of Presentation:

On-demand Webcast (CLE)

 

Prerequisite:

General knowledge of patent laws

 

Course Code:

148678

 

NY Category of CLE Credit:

Areas of Professional Practice

 

Total Credits:

1.5 CLE


How to Claim CLE Credits Per State:

https://knowledgewebcasts.com/how-to-claim-cle-credits-per-state/


CLE State Requirements:

https://knowledgewebcasts.com/cle-state-requirements/

Speaker Panel:

Brendan Gavin, Attorney
White & Case

Brendan is an associate in the Intellectual Property Group at White & Case and has more than 10 years of experience working in the field of patent law.  His practice focuses on a variety of intellectual property issues, including worldwide patent portfolio development, patent prosecution, due diligence, and litigation support.  Brendan has extensive experience providing freedom-to-operate, invalidity and patentability opinions, and he also assists the patent litigation group in contested proceedings, such as inter partes review and post grant review proceedings.  Brendan regularly works with clients and inventors from large corporations, start-up companies and universities to develop ideal intellectual property protection strategies of technologies such as enzyme replacement therapies, modified polypeptides, fusion proteins, small molecules, nucleic acid therapeutics (including CRISPR and RNAi), antibody development, methods of treatment, diagnostic methods, drug formulations, and dosage regimens.

Leslie Kushner, Litigation Counsel
Pearl Cohen Zedek Latzer Baratz LLP

Leslie Kushner is Counsel in the Litigation Group at Pearl Cohen’s New York office. She is an experienced intellectual property attorney, with extensive background in life sciences, biotechnology, and biochemistry. Dr. Kushner utilizes her decades of experience as a biomedical research scientist to represent clients in complex patent (including Hatch-Waxman), trade secret, and contract litigation across various industries, focusing her practice on chemical, biotechnological, pharmaceutical, diagnostic and medical device matters. She also counsels clients on patent validity and freedom-to-operate, performs intellectual property due diligence investigations, and negotiates and drafts licensing, joint venture, and consulting agreements.

Dr. Kushner’s experience includes patent infringement litigation pertaining to pharmaceutical and biotechnological inventions, trade secret litigation pertaining to drug formulations and educational services, copyright litigation pertaining to the entertainment industry, and contract litigation pertaining to biotechnological methods and educational services. Dr. Kushner has provided professional opinions on small-molecule pharmaceuticals, antibodies, cytokines, oligonucleotides, siRNA, enzyme inhibitors, and automotive parts, and has performed due diligence analyses for firms in the pharmaceutical, biotechnological, food, and gaming industries.

Agenda:

  • Guiding Principles for Patent Eligibility
  • Updated Framework for Patent Eligibility
  • Section 101, 102, & 103 Conundrums
  • Impacts on Biotech and Chemical Patent
  • What Lies Ahead

Date & Time:

Tuesday, January 14, 2020

3:00 pm to 4:30 pm (ET)

Materials:

Download Course Materials

Who Should Attend:

  • Patent Lawyers and Consultants
  • Patent Agents
  • Intellectual Property Lawyers
  • Patent Examiners
  • Corporate Counsel
ImageNameCategory

SPEAKERS

Brendan GavinAttorney
White & Case
Leslie KushnerLitigation Counsel
Pearl Cohen Zedek Latzer Baratz LLP

SUBSCRIPTION PACKAGES

ALL-ACCESS PASS

View Details

CLE LAW MONTHLY

View Details

CPE FINANCE MONTHLY

View Details

Join Over 150,000 Professionals Empowering Their Careers

Learn anywhere from over 1800+ live and recorded CLE CPE & Technology webcasts.